NCT00613249View on ClinicalTrials.gov

A Phase I Pharmacokinetics and Safety Study of Two Dapivirine Intravaginal Gels

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions
HIV Infections
Interventions
DRUG

Dapivirine Gel 4750, 0.05%, 2.5g

intravaginal gel, dosed daily

DRUG

Dapivirine Gel 4789, 0.05%, 2.5g

intravaginal gel, dosed daily

DRUG

HEC-based Placebo Gel

intravaginal gel, dosed daily

Trial Locations (1)

B-2060

SGS Life Science Services Research Unit Stuivenberg, Antwerp

All Listed Sponsors
lead

International Partnership for Microbicides, Inc.

INDUSTRY

NCT00613249 - A Phase I Pharmacokinetics and Safety Study of Two Dapivirine Intravaginal Gels | Biotech Hunter | Biotech Hunter